New in AML

Our "New in AML" articles cover treatment option updates, coverage of advancements from major AML academic meetings, and more.

Recent Articles

A New Treatment Option Being Investigated For High Risk MDS And AML Patients

November 09, 2023

mds, aml, life with aml, new in aml, Bemcentinib and aml, trials for aml

Dr. Chandhok - Improving Drug Efficacy for Underserved Populations

August 22, 2023

Dr. Chandhok is doing important research into improving drug efficacy for underserved populations.

Revumenib Targets KMT2A And NPM1 Mutations

August 07, 2023

The menin protein is an important factor in both KMT2A and NPM1 versions of AML.

Breaking News: FDA Approves Quizartinib for FLT3 Positive Acute Myeloid Leukemia

July 21, 2023

The U.S. Food and Drug Administration (FDA) grants approval for a new therapy called quizartinib for FLT3 positive acute myeloid leukemia.

ASCO 2023: Patient Preferences are Important in Determining AML Treatment

July 13, 2023

HealthTree spoke with Dr. Loh at ASCO 2023 about the importance of shared decision making for AML patients.

ASCO 2023: Early Testing of a Drug for P53 Mutated AML with Dr. Pardee

July 10, 2023

HealthTree spoke with Dr. Pardee at ASCO 2023 about his early research looking at a possible new drug option for those with P53 mutated AML.

ASCO 2023: Dr. Swoboda’s Work on Genetic Sequencing, Macrophages and BCL-2 Inhibitors for AML at Tampa General

June 26, 2023

HealthTree spoke with Dr. Swoboda at ASCO 2023 about the important work he is doing on AML at Tampa General Hospital.

Omidubicel Granted FDA Approval For Blood Cancer Patients Eligible for Umbilical Cord Blood Transplant

May 01, 2023

For more than 30 years, umbilical cord blood (UCB) has been an important stem cell source for patients with leukemia, lymphoma and MDS

The Importance Of Residual Disease Testing Before Transplant

April 27, 2023

Residual disease may still be present even when a patient is considered “in remission”. Lingering traces of leukemia make a transplant less effective.

Dr. Tinsley-Vance - Improving the AML Patient Treatment Experience

April 25, 2023

The work Dr. Tinsley-Vance is doing is important and will have a big impact on the way we look at patient decision making and our support of caregivers.

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

New in AML

Recent Articles

Get the latest thought leadership on Acute Myeloid Leukemia delivered straight to your inbox.

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Follow Us